NICE forced to rethink decision on AMD drug

The National Institute for Health and Clinical Excellence (NICE) has been forced to rethink its controversial decision to restrict the use of Lucentis and Macugen on the NHS to treat patients with wet age-related macular degeneration (AMD) in England and Wales.

A meeting scheduled to take place on Monday was cancelled by NICE and instead the body said in a statement: 'A rescheduled committee date is planned for the autumn to discuss the revised economic model as well as responses to the consultation, and it is anticipated that a second appraisal consultation document will be released following the meeting.